SCHEMBL305332

SCHEMBL305332

[CH2]c1oc(=O)oc1-c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.38
MEN1 O00255 4/20 0.38
CYP3A4 P08684 4/20 0.38
KMT2A Q03164 4/20 0.38
LMNA P02545 3/20 0.38
ALOX15 P16050 3/20 0.38
ADORA3 P0DMS8 3/20 0.38
TP53 P04637 2/20 0.38
MAPK1 P28482 2/20 0.38
CA12 O43570 2/20 0.38
ABCB1 P08183 2/20 0.38
CYP1B1 Q16678 2/20 0.38
DDR2 Q16832 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CALM1 P0DP23 1/20 0.38
AR P10275 1/20 0.38
PKM P14618 1/20 0.38
CA9 Q16790 1/20 0.38
MAPT P10636 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL48083 0.84 KDM4E (0.44) KDM4EMEN1CYP3A4KMT2ALMNA
SCHEMBL453197 0.79 TP53 (0.39) KDM4EMEN1KMT2ALMNAALOX15
SCHEMBL449196 0.79 NOTUM (0.38) KDM4EMEN1KMT2ALMNAABCB1
SCHEMBL448674 0.75 MEN1 (0.49) KDM4EMEN1CYP3A4KMT2AADORA3
SCHEMBL10179796 0.74 CTRC (0.38) KDM4EMEN1CYP3A4KMT2ALMNA
SCHEMBL981801 0.74 ABCG2 (0.40) KDM4EMEN1CYP3A4KMT2ALMNA
SCHEMBL306962 0.71 KDM4E (0.33) KDM4EMEN1CYP3A4KMT2ALMNA
SCHEMBL2721048 0.69 KDM4E (0.35) KDM4EMEN1CYP3A4KMT2ALMNA
SCHEMBL5492196 0.69 ADORA3 (0.39) KDM4EMEN1CYP3A4KMT2ALMNA
SCHEMBL22356152 0.69 KDM4E (0.44) KDM4EMEN1CYP3A4KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 832 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018174839-A1 CYSTEINE, N-ACETYLCYSTEINE AND PENICILLAMINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE NGUYEN MARK QUANG (US) 2018-09-27 WO claimed
US-9963428-B1 Bucillamine prodrugs, pharmaceutical compositions thereof, and methods of use Nguyen, Mark Quang (US) 2018-05-08 US claimed
US-9676720-B2 Substituted biaryl compound UBE INDUSTRIES, LTD. (JP) 2017-06-13 US claimed
US-8658639-B2 N-substituted-cyclic amino derivative DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2014-02-25 US claimed
EP-2415474-B1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF OPHTHALMIC DISEASES UBE INDUSTRIES (JP) 2013-08-28 EP claimed
EP-2221308-B1 BENZAZEPINONE COMPOUND UBE INDUSTRIES (JP) 2013-07-10 EP claimed
US-8377922-B2 Benzazepinone compound UBE INDUSTRIES, LTD. (JP) 2013-02-19 US claimed
US-20120302614-A1 METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER OSAKA UNIVERSITY (JP) 2012-11-29 US claimed
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-05-17 US claimed
EP-2447264-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-05-02 EP claimed
EP-0191044-B1 DERIVATIVES OF METHYLENE-BISPHOSPHONIC ACID, PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) 1990-02-07 EP claimed
US-4898862-A 1,2,4-triazinone derivatives, their preparation and use SANKYO COMPANY LIMITED (JP) 1990-02-06 US claimed
EP-0307872-A2 Esters of amino-acids, process for their preparation, medicaments containing them and their use HOECHST AKTIENGESELLSCHAFT (DE) 1989-03-22 EP claimed
EP-0295100-A1 Methoxymethyl compounds FARMITALIA CARLO ERBA S.r.l. (IT) 1988-12-14 EP claimed
US-4734410-A Lactam derivatives and their use as hypotensive agents SANKYO COMPANY LIMITED (JP) 1988-03-29 US claimed
US-4732998-A Bisphosphonic acids and esters LEO PHARMACEUTICAL PRODUCTS, LTD. (DK) 1988-03-22 US claimed
US-4699905-A HYPOTENSIVE AGENTS SANKYO COMPANY, LIMITED (JP) 1987-10-13 US claimed
EP-0191044-A1 DERIVATIVES OF METHYLENE-BISPHOSPHONIC ACID, PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION. LEO PHARM PROD LTD (DK) 1986-08-20 EP claimed
WO-1986000902-A1 DERIVATIVES OF METHYLENE-BISPHOSPHONIC ACID, PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 1986-02-13 WO claimed
EP-0161801-A2 Perhydrothiazepine derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1985-11-21 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302614-A1 METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER AGTR2, AGTR1, BDKRB2 KDM4E 4538/4885MEN1 3642/4885CYP3A4 2864/4885
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE REN, AGTR1, AGTR2 KDM4E 2147/4885MEN1 1004/4885CYP3A4 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.